Defeating Schizophrenia is Good

After years of research and horrible treatments, a new path of treatment is promising and just hitting the market.

TL;DR

Schizophrenia affects approximately 24 million people worldwide. In the United States alone, it affects about 1% of the population, or approximately 3.2 million people. The economic burden of schizophrenia is substantial, with annual costs exceeding $150 billion in the United States. These costs include healthcare expenses, lost productivity, and social welfare programs.

Historically, fighting it has been brutal and medieval. Some of the horrific treatments that were once employed include lobotomies, insulin shock therapy, and electroshock therapy. These treatments often caused significant harm and suffering in and of themselves, highlighting the desperate need for something more effective and humane.

That something is an innovative new treatment called Cobenfy (incidentally, the prior name to this drug was KarXT which is a sweeter name.)

But this drug is today’s good thing.

More after the bump.